The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Persistent Symptomatic Hypocalcemia Due to Denosumab: A Case Review

Persistent Symptomatic Hypocalcemia Due to Denosumab: A Case Review

October 1, 2014 • By Lyudmila Kirillova, MD, & William Ayoub, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Persistent Symptomatic Hypocalcemia Due to Denosumab
Osteoporosis is more prevalent in aging populations, who often have other issues, such as impaired renal function.

Osteoporosis is a serious, but preventable condition. Hip and vertebral fractures are associated with increased disability, mortality and prolonged care at nursing facilities. In 2005, it was estimated that the cost of osteoporosis-related fractures totaled $17 billion.1

You Might Also Like
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Denosumab Does Not Stimulate Early Bone Formation
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
Explore This Issue
October 2014

Osteoporosis is more prevalent in aging populations, who often have multiple comorbidities. Patients with impaired renal function are especially challenging because they have a higher incidence of osteoporosis and metabolic bone disease associated with chronic kidney disease (CKD). This includes adynamic bone disease, uremic osteodystrophy, and abnormalities of parathyroid hormone (PTH), vitamin D, calcium and phosphorus. Treatment options are limited in patients with chronic kidney disease (CKD) because bisphosphonates are contraindicated when the creatinine clearance is below 35 mL/min.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Denosumab was approved by the Food and Drug Administration for treatment of osteoporosis in 2010 and is one of the few medications that has been used as a treatment option in patients with CKD.2 Denosumab is a human monoclonal antibody with affinity to receptor activator of nuclear factor kappa B ligand (RANKL). It prevents RANKL/RANK interaction, leading to inhibition of osteoclast formation, function and survival.2 We report the development of persistent and symptomatic hypocalcemia in an older patient who was treated with this drug.

We suggest caution when using denosumab in patients with severe renal impairment (GFR <30 mL/min).

Case

A 79-year-old man with a history of gout, rheumatoid arthritis treated with corticosteroids, type 2 diabetes mellitus and stage 4 CKD due to focal segmental glomerulo­sclerosis was evaluated at a rheumatology clinic for increased risk for future fracture based on low T scores of –1.9 at the lumbar spine and –1.7 at the femoral neck. The FRAX (Fracture Risk Assessment Tool) calculated 10-year risk for hip fracture was 5.5%. His creatinine was 2.7 mg/dL (normal 0.5–1.0 mg/dL) with an estimated GFR of 25 mL/min (normal >60 mL/min), calcium 9.1 mg/dL (normal 8.3–10.5), 25 (OH) vitamin D 25.0 mg/mL (normal 30–100), phosphorus 3.4 mg/dL (normal 2.5–4.8 mg/dL) and PTH 108 pg/mL (normal 15–65). Sixty mg of denosumab via subcutaneous injection was given to the patient as an approved option in patients with CKD. Prior to injection, the patient was taking 600 mg a day of calcium carbonate and 1,000 units/day of vitamin D3.

Table 1: Summary of Laboratory Data & Medications Adjustment
click for large version
Table 1: Summary of Laboratory Data & Medications Adjustment

Two weeks later, the patient developed malaise and upper extremity weakness. Within several days, he was admitted to the hospital with fever of 39.6ºC, malaise, myalgia, tremor, irritability and paresthesias. He was found to have severe hypocalcemia with a calcium level of 5.5 mg/dL, ionized calcium of 0.90 mmol/L (1.13–1.32 mmol/L), PTH 190 and creatinine of 3.1 mg/dL. He was evaluated by rheumatology, endocrinology and nephrology, and was diagnosed with hypocalcemia due to denosumab. The patient was treated with IV calcium for four days and subsequently transitioned to oral calcium carbonate 2,250 mg four times a day, and calcitriol 0.25 mg daily. The patient remained in the hospital for eight days due to persistent hypocalcemia. At discharge, his serum calcium was 9.0, creatinine was 2.5 and he was discharged on calcium carbonate 1,500 mg four times a day and calcitriol 0.25 mg daily.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: Ayoub, Clinical, denosumab, hypocalcemia, Kirillova, Osteoarthritis, Osteoporosis, patient care, Renal, rheumatologist, SteroidsIssue: October 2014

You Might Also Like:
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Denosumab Does Not Stimulate Early Bone Formation
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • Denosumab Linked to Rebound-Associated Fractures in Nine Patients

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.